Plain-English translation of NCT07789574 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether asciminib, a newer medication, works well for people with chronic myeloid leukemia (CML) who have a specific genetic change called the T315I mutation. This mutation can make leukemia resistant to standard treatments. The study will follow 50 patients across about 20 hospitals in Germany to see how well this medication controls their cancer.
People with CML who develop the T315I mutation often stop responding to standard leukemia drugs, leaving them with limited treatment options. This trial exists to see if this medication can help patients for whom other treatments have stopped working.
You likely qualify if…
You likely don't qualify if…
You would take the medication twice daily at home for at least 2 years while being monitored by your medical team. You would have regular clinic visits (typically every few weeks to months) for blood tests, heart rhythm checks, and physical exams to make sure the medication is working and that you're tolerating it well. The entire study lasts about 4 years, including enrollment and follow-up, but your personal involvement would focus on the treatment period and ongoing monitoring.
AI-generated summary from trial data · Nov 13, 2026 · Not medical advice
Germany